What Aptorum Group does

Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) is a clinical-stage biopharmaceutical company founded in 2017 by Ian Huen and headquartered in London, with operational offices in New York, Singapore, Hong Kong, and Mississauga. The company develops therapeutic assets targeting unmet medical needs in oncology (including orphan oncology indications), infectious diseases, and autoimmune disorders, supported by two proprietary drug-discovery platforms: the Smart-Act series, which systematically screens existing approved molecules for new indications, and the Acticule series, focused on oncology and infectious disease therapeutics. Aptorum also co-developed a molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (A*STAR).

Aptorum's business model is primarily pre-revenue: therapeutic development relies on future one-time licensing or commercialization economics, and the company has historically funded operations through equity offerings (e.g., a $3M registered direct offering in January 2025, up to $6M in October 2025) and a $3M convertible note subscribed by Aenco Technologies Limited in December 2022. In July 2025, Aptorum entered a definitive all-stock merger with DiamiR Biosciences Corp. — approved by shareholders in June 2026 and expected to close before fiscal 2027 — which would add recurring diagnostic-services revenue through DiamiR's CLIA-certified, CAP-accredited laboratory, including an APOE testing platform validated in partnership with Instant NanoBiosensors and published microRNA biomarker signatures for glioblastoma detection. Post-merger headquarters is planned for Princeton, New Jersey.

Following the merger, Aptorum would target healthcare providers, clinical laboratories, and pharmaceutical partners across North America, Europe, and East/Southeast Asia. Customer concentration is presently undefined given the absence of commercial revenue; the company employs between 11 and 50 staff and has experienced recurring operating losses. As of March 2026, the company was under a Nasdaq minimum bid price deficiency notice with sub-$1 trading and a 180-day compliance grace period expiring September 1, 2026.

Name

Aptorum Group

Legal name

Aptorum Group Limited

Website

https://aptorumgroup.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Aptorum Group is a clinical-stage biopharmaceutical company developing therapeutic assets in oncology, infectious disease, and autoimmune disorders via its Smart-Act and Acticule platforms, and, through a pending merger with DiamiR Biosciences, blood-based diagnostics for glioblastoma and Alzheimer's disease.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceutical and diagnostics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

akta.pro secondary industries

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG)

Keywords

• Clinical-stage biopharmaceutical
• Oncology therapeutics development
• Infectious disease drug discovery
• Drug repurposing platforms
• Molecular diagnostic testing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic asset commercialization: Pre-revenue clinical-stage biopharmaceutical company developing therapeutic assets in oncology, autoimmune, and infectious diseases. Revenue expected upon successful clinical development and regulatory approval.
2. Diagnostic services: Following merger with DiamiR Biosciences, Aptorum will generate revenue from clinical laboratory diagnostic services including APOE testing for Alzheimer's disease and microRNA-based tests for glioblastoma, operated through DiamiR's CLIA-certified, CAP-accredited laboratory.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Aptorum Group is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its pipeline is enriched by drug discovery platforms enabling systematic screening of approved drug molecules, a microbiome-based research platform for metabolic diseases, and a co-developed molecular rapid pathogen identification and detection diagnostics technology. Following the pending merger with DiamiR Biosciences, Aptorum will also offer blood-based diagnostic tests for brain health conditions including Alzheimer's disease and glioblastoma.

Product overview

Aptorum Group is a clinical-stage biopharmaceutical company with a diversified product portfolio comprising two drug development series (Smart-Act Series and Acticule Series) focused on therapeutic assets in oncology and infectious diseases, along with a proprietary molecular rapid pathogen identification and detection diagnostics technology developed in partnership with Accelerate Technologies Pte Ltd. The company also operates drug discovery platforms enabling systematic screening of existing approved drug molecules and microbiome-based research for metabolic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Smart-Act Series

Quantifiable outcome

• Non-invasive blood plasma test for glioblastoma detection using microRNA signatures published in peer-reviewed journal Diagnostics
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• New York University (NYU)minorStrategic or Co-development Partner · 19 November 2025DiamiR Biosciences and Aptorum Group collaboration with NYU for microRNA biomarker research for neurodegeneration, with findings presented at CTAD 2025 Conference. Research funded by NIH grants.
• University of PennsylvaniaminorStrategic or Co-development Partner · 19 November 2025DiamiR Biosciences and Aptorum Group collaboration with University of Pennsylvania for microRNA biomarker research for neurodegeneration, with findings presented at CTAD 2025 Conference. Research funded by NIH grants.
• DiamiR Biosciences CorpcoreStrategic or Co-development Partner · 16 July 2025Aptorum Group announced a definitive all-stock merger agreement with DiamiR Biosciences, with DiamiR becoming a wholly-owned subsidiary. The merger was approved by shareholders of both companies on June 9-10, 2026 and is expected to close before fiscal 2027. The combined entity will focus on blood-based tests for brain health and other diseases, headquartered in Princeton, New Jersey. DiamiR brings CLIA-certified, CAP-accredited clinical laboratory capabilities and proprietary microRNA biomarker technology.
• Accelerate Technologies Pte LtdcoreStrategic or Co-development PartnerCo-development of novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of Singapore's Agency for Science, Technology and Research (A*STAR).
• Covar PharmaceuticalsminorStrategic or Co-development PartnerDevelopment site in Canada operated in partnership with Covar Pharmaceuticals for drug development activities.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Catalyst Pharmaceuticals: Catalyst Pharmaceuticals (CPRX) is explicitly cited as the primary peer comparator in Aptorum's revenue analysis. Both are small-cap clinical-stage biopharmaceutical companies with oncology/orphan disease focus, providing a direct benchmark for Aptorum's scale and pipeline economics.
• DiamiR Biosciences: DiamiR is Aptorum's announced merger target and will become a wholly-owned subsidiary. Both companies share the microRNA biomarker platform focus and overlap directly on blood-based diagnostics for brain health (glioblastoma and Alzheimer's), making them direct operating peers in the combined entity.
• C2N Diagnostics: C2N Diagnostics is a clinical-stage diagnostics company developing blood-based biomarker tests for Alzheimer's disease, including PrecivityAD. Directly comparable to Aptorum/DiamiR's planned APOE testing platform for Alzheimer's, serving the same neurology providers and patient population.
• Quanterix: Quanterix (QTRX) develops ultra-sensitive biomarker detection platforms including microRNA-based assays used in neurology and oncology research. Directly comparable on the underlying microRNA detection technology and blood-based neurology biomarker applications that Aptorum/DiamiR are pursuing.
• Algernon Pharmaceuticals: Algernon Pharmaceuticals is a small clinical-stage biopharmaceutical company focused on drug repurposing for CNS and other indications. Closely comparable to Aptorum's Smart-Act drug discovery platform that systematically screens existing approved drug molecules for new therapeutic applications.
• Aprea Therapeutics: Aprea Therapeutics (APRE) is a clinical-stage oncology biopharmaceutical company with a similar small-cap profile. Comparable to Aptorum in therapeutic area focus (oncology), pipeline maturity (early-stage clinical assets), and capital-raising pattern typical of small public biotechs.
• Diffusion Pharmaceuticals: Diffusion Pharmaceuticals (DFFN) is a small clinical-stage biopharmaceutical with similar scale, public listing dynamics, and pipeline profile. Provides a comparable benchmark for Aptorum's market capitalization, liquidity profile, and small-cap public biotech economics.

Emerging players

• Cassava Sciences: Cassava Sciences (SAVA) is a clinical-stage biopharmaceutical focused on Alzheimer's disease therapeutics and diagnostics. Comparable on the brain health/neurology focus that overlaps with the DiamiR-merged Aptorum diagnostics franchise and the broader neurology indication strategy.
• Prothena Corporation: Prothena (PRTA) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Alzheimer's. Comparable to Aptorum's therapeutic development ambitions in neurology and infectious disease, with a more advanced pipeline but similar disease-area focus.

Broad incumbents

• Bio-Techne: Bio-Techne (TECH) is an established life sciences tools and diagnostics company that provides reagents and platforms for biomarker research including microRNA detection. Comparable as a broader incumbent in the diagnostic tools and reagents space that Aptorum/DiamiR will compete within for neurology biomarker applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptorum Group